In summary, our results confirm that a high SIRT2 expression level is related to the unfavorable prognosis of patients with AML; therefore, SIRT2 may be a new risk stratification marker, particularly for poor-risk patients with AML, and a new target for clinical therapy. Here, SIRT2 is linked to acute myeloid leukemia.